Effect of absolute monocyte count post-transplant on the outcome of patients with acute myeloid leukemia undergoing myeloablative allogeneic hematopoietic stem cell transplant with busulfan and cyclophosphamide conditioning. (June 2018)

• Record Type: Journal Article
• Authors: Tang, Liyuan; Wang, Na; Xing, Chongyun; Zhuang, Qiang; Liang, Bin; Sun, Lan; Chen, Yi; Qian, Yan; Shen, Zhijian; Jiang, Songfu; Yu, Kang; Feng, Jianhua
• Is Part Of: Leukemia research. Volume 69(2018)
• Page Start: 60
• Page End: 65
• Publication Date: 2018-06
• Subjects: Acute myeloid leukemia -- Absolute monocyte count -- Myeloablative allogeneic hematopoietic stem cell transplant -- Prognosis -- Survival; Leukemia -- Periodicals; Leukemia -- Periodicals; Leucémie -- Périodiques; Leukemia; Periodicals; Electronic journals; Electronic journals; 616.9941905
• DOI: 10.1016/j.leukres.2018.04.006
• Languages: English
• ISSNs: 0145-2126

Abstract

Highlights: High AMC on PTD 15 is associated with improved platelet engraftment. AMC on PTD 15 has no impact on CIR and non-relapse mortality. Patients with a high AMC on PTD 15 have a worse OS and post-relapse survival. Abstract: Peripheral monocytes have recently been evaluated as a prognostic factor in different types of hematological malignancies. This study assessed the prognostic value of absolute monocyte count (AMC) post-transplant on the clinical outcomes of 59 patients with acute myeloid leukemia (AML) who had undergone myeloablative conditioning (MAC) allogeneic hematopoietic stem cell transplant (allo-HSCT) with busulfan and cyclophosphamide (Bu/Cy). Kaplan-Meier analysis showed that patients with a high AMC (≥ 0.57 × 10 9 /L) on post-transplant day (PTD) 15 had a significantly worse overall survival (OS) compared to patients with a low AMC (< 0.57 × 10 9 /L) on PTD 15 (P = .0049). Univariate Cox proportional hazard analyses revealed that only high AMC on PTD 15 was a poor prognostic factor for OS (P = .008) and post-relapse survival (P = .030). We conclude that AMC ≥ 0.57 × 10 9 /L on PTD 15 is associated with more deaths in patients with AML who have undergone MAC allo-HSCT with Bu/Cy.